Company news

Cytokinetics, Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

September 5, 2023

Cytokinetics Reports Second Quarter 2023 Financial Results

August 2, 2023

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

July 31, 2023

Cytokinetics to Announce Second Quarter Results on August 3, 2023

July 26, 2023

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

June 19, 2023

Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

May 19, 2023

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress

May 14, 2023

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586

May 10, 2023

Cytokinetics to Participate in the JMP Securities Life Sciences Conference

May 7, 2023

Cytokinetics Reports First Quarter 2023 Financial Results

May 3, 2023

Cytokinetics to Announce First Quarter Results on May 4, 2023

April 19, 2023

Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference

April 9, 2023

Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis

March 30, 2023

Cytokinetics Releases Inaugural Corporate Responsibility Report

March 26, 2023

Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session

March 3, 2023

Cytokinetics Reports Fourth Quarter 2022 Financial Results

February 28, 2023

Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil

February 27, 2023

Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session

February 23, 2023

Cytokinetics to Announce Fourth Quarter Results on March 1, 2023

February 14, 2023

Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program

January 29, 2023

Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

December 12, 2022

Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil

December 8, 2022

Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND

December 7, 2022

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

December 6, 2022

Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND

November 30, 2022

Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022

November 6, 2022

Cytokinetics Reports Third Quarter 2022 Financial Results

November 2, 2022

Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022

October 30, 2022

Cytokinetics to Announce Third Quarter Results on November 3, 2022

October 19, 2022

Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis

October 9, 2022

Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program

September 27, 2022

Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting

September 25, 2022

Cytokinetics Reports Second Quarter 2022 Financial Results

August 3, 2022

Cytokinetics to Announce Second Quarter Results on August 4, 2022

July 20, 2022

Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering

June 30, 2022

Cytokinetics Announces Proposed Convertible Senior Notes Offering

June 28, 2022

Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil

June 23, 2022

Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil

June 16, 2022

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

June 15, 2022

Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

June 12, 2022

Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

June 2, 2022

Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress

May 22, 2022

Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil

May 16, 2022

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress

May 15, 2022

Cytokinetics Reports First Quarter 2022 Financial Results

May 3, 2022

Cytokinetics to Announce First Quarter Results on May 4, 2022

April 19, 2022

Cytokinetics Announces Changes to Board of Directors

April 7, 2022

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session

April 2, 2022

Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session

April 1, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 44 decks. Every deck is listed under its year.